Sign In
Buy OPT
$3.41
+0 (+0%)
At Close: Jun 30, 2025
Opthea Appoints John Han, PharmD, as VP Medical Affairs
06:42pm, Monday, 08'th Apr 2024
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing nov
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
06:34pm, Thursday, 04'th Apr 2024
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing nov
Opthea Appoints Sujal Shah to the Board of Directors
05:39pm, Wednesday, 03'rd Apr 2024
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leade
7 Growth Stocks to Buy to Outperform the Nasdaq Index
09:53am, Wednesday, 03'rd Apr 2024
As investors, we all aim to outperform the market. But beating the S&P 500 is a difficult task for most of us.
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
06:00am, Tuesday, 19'th Mar 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies t
Opthea to Participate in the Leerink Partners Global Biopharma Conference
05:08pm, Tuesday, 05'th Mar 2024
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly preva
Opthea Reports Half-Year Financial Results and Business Updates
05:55pm, Wednesday, 28'th Feb 2024
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
06:25pm, Monday, 19'th Feb 2024
Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
07:00am, Wednesday, 14'th Feb 2024
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD
Opthea Strengthens Team with Key Clinical and Regulatory Hires
06:00am, Thursday, 01'st Feb 2024
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseas
Opthea to Receive US$35M Commitment and Additional US$50M Funding
06:00am, Wednesday, 27'th Dec 2023
MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea Receives A$8.8 million R&D Tax Incentive
06:00am, Tuesday, 19'th Dec 2023
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at the FLORetina 2023 Congress
05:30am, Friday, 01'st Dec 2023
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at the Jefferies 2023 London Healthcare Conference
05:30am, Thursday, 09'th Nov 2023
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
05:30am, Monday, 30'th Oct 2023
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
